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Type 2 diabetes mellitus is characterized by a rela-
tive deficit in insulin secretion, caused by a de-
crease in the glucose sensitivity of the pancreatic 
beta cells, by a reduction in their total number, 
or a combination of both. Not surprisingly, a great 
deal of effort is expended in understanding the 
processes that underlie these events and how 
they go awry in type 2 diabetes. One line of in-
vestigation involves dissection of the mechanisms 
by which glucose triggers insulin secretion; a re-
cent article by Ohtsubo and colleagues1 under-
scores an interesting process.
Glucose-stimulated insulin secretion requires 
the metabolism of glucose, and consequent events 
induce an influx of calcium, which, in turn, in-
duces exocytosis of granules containing insulin 
(Fig. 1). Biochemical studies and genetic analy-
sis of patients with adult-onset diabetes of the 
young type 2 have shown that the insulin-secre-
tory activity of beta cells — which is proportional 
to the dose of glucose — is controlled by the ki-
netics of glucokinase, the enzyme that converts 
glucose into glucose-6-phosphate.
Before glucokinase can act on glucose, how-
ever, glucose must be transported across the beta-
cell membrane into the cytoplasm — a process 
mediated by the glucose transporter 2 (GLUT-2). 
In physiologic situations, transmembrane trans-
port mediated by GLUT-2 provides glucose with 
unrestricted access to glucokinase. But GLUT-2 
expression is tightly regulated in beta cells and 
markedly reduced in the diabetic state when 
glucose-stimulated insulin secretion is impaired. 
This process can be caused by elevated levels of 
free fatty acids or glucocorticoids or by a reduc-
tion in the level of specific transcription factors, 
such as pancreas duodenum homeobox1 or hep-
atocyte nuclear factor 1α. Whether decreased 
transporter expression in these contexts is suf-
ficient to suppress glucose-stimulated insulin se-
cretion has been difficult to evaluate because the 
modified expression of other proteins could co-
operate to deregulate secretion. However, studies 
of knockout and transgenic mice have shown that 
impaired glucose-stimulated insulin secretion 
develops when GLUT-2 is reduced by 80 percent 
or more.2,3
Ohtsubo et al. described a novel mechanism 
that controls cell-surface expression of GLUT-2 in 
beta cells. With the use of transgenic technology, 
they engineered mice that lack an enzyme that 
resides in the Golgi apparatus and that transfers 
the terminal sugar to the oligosaccharide side 
chains of GLUT-2. (The enzyme, N-acetylglucos-
amine transferase 4a, is encoded by Mgat4a.) Strik-
ingly, these mice were hyperglycemic and hypo-
insulinemic and had impaired glucose tolerance; 
in addition, the first phase of insulin secretion 
was suppressed and the second phase was mut-
ed — which is very similar to the defect seen in 
type 2 diabetes and in Glut2-deficient mice. Analy-
sis of the islets of the Mgat4-deficient mice re-
vealed very low expression of GLUT-2 at the cell 
surface of beta cells and a poor capacity for glu-
cose uptake. The authors then showed that the 
low surface expression of GLUT-2 is due to a mod-
ification in the structure of the GLUT-2 N-glycan, 
which is unable to interact with a cell-surface 
lectin, galectin-9 (also known as the urate trans-
porter). The investigators showed that this inter-
action is essential to retain wild-type GLUT-2 (but 
not other membrane proteins) at the cell surface.
Of particular interest is the discovery by 
Ohtsubo et al. that feeding normal mice a high-
fat diet, which is known to affect insulin secre-
tion negatively, strongly down-regulated the ex-
pression of N-acetylglucosamine transferase 4a. 
This was accompanied by the modified GLUT-2 
N-glycan structure, diminution of GLUT-2 expres-
sion at the cell surface, and impaired glucose-
stimulated insulin secretion.
The extent to which MGAT4A is relevant to hu-
man diabetes may be difficult to evaluate, because 
human beta cells express other glucose transport-
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Figure 1. Control of Glucose Transport.
Glucose-stimulated insulin secretion in a beta cell is initiated by glucose uptake by the glucose transporter GLUT-2, 
followed by glucose metabolism through the glycolytic pathway, and the generation of adenosine triphosphate 
(ATP). The increase in the ratio of ATP to adenosine diphosphate (ADP) closes an ATP-dependent potassium (K+) 
channel, which leads to plasma-membrane depolarization, and influx of calcium (Ca2+) through a voltage-gated 
 calcium channel. The increase in intracellular Ca2+ then leads to the exocytosis of insulin granules. In normal 
 conditions (Panel A), the characteristic dose-dependence of insulin secretion is controlled by the phosphorylation of 
glucose by glucokinase. A recent study by Ohtsubo et al.1 showed that retention of GLUT-2 in the plasma membrane 
requires interaction between the GLUT-2 N-glycan and a cell-surface lectin, galectin-9. When this interaction is 
 suppressed by genetic inactivation of the glycosyltransferase that controls the structure of the N-glycan (Panel B), 
GLUT-2 is internalized and relocates to endosomes and lysosomes, and its cell-surface expression is reduced by 
 approximately 90 percent. Glucose uptake is limited and glucose-stimulated insulin secretion is impaired.
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ers in addition to GLUT-2, such as GLUT-1 and 
GLUT-3, which may, at least in part, compensate 
for the absence of GLUT-2. Nevertheless, linkage 
studies have shown an association of DNA se-
quence variants in or near GLUT-2 with diabetes 
in some groups. Moreover, patients with the 
Fanconi–Bickel syndrome — caused by mutation 
of GLUT-2 — often present with postprandial 
hyperglycemia and reduced insulin levels sugges-
tive of beta-cell secretion defects. If the mecha-
nism described by Ohtsubo et al. operates in 
human islets, it may represent a link between a 
high-fat diet and the development of type 2 dia-
betes. Furthermore, mutations in MGAT4A or oth-
er glycosyltransferase genes, the protein products 
of which modify the normal structure of the 
GLUT-2 N-glycan, may also lead to impaired in-
sulin secretion and thereby cause type 2 diabetes.
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